NeuroSense Adds New Data To PrimeC Application, Delays Health Canada Filing To March 2027
NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
HC Wainwright & Co. Downgrades NeuroSense Therapeutics to Neutral
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
Neurosense Therapeutics Inks Collaboration Agreement To Advance Supply Of PrimeC To Treat Amyotrophic Lateral Sclerosis
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
NeuroSense Therapeutics Announces Nasdaq Hearings Panel Date Of November 10; Minimum Bid Price Compliance Already Regained; Sees PrimeC Milestones In December And Q1 2027
NeuroSense Provides Update on Nasdaq Listing Compliance
NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52
NeuroSense Provides Business Update and Progress for the First Half of 2026
NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
NeuroSense Therapeutics Announces 1-For-20 Reverse Stock Split, Effective Sept. 14
HC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
NeuroSense Announces Redesigned Development Plan For PrimeC In Amyotrophic Lateral Sclerosis, Structured To Reach Potential Path For Regulatory Submission And Faster Approval
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.